Evidence map›Paper›PMID 39211737›Full record

ArticleFrontiers in genetics2024

SAFE-MIL: a statistically interpretable framework for screening potential targeted therapy patients based on risk estimation.

Yanfang Guan, Zhengfa Xue, Jiayin Wang, Xinghao Ai, Rongrong Chen, Xin Yi, Shun Lu, Yuqian Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanfang Guan *School of Computer Science and Technology, Xi'an Jiaotong University, Xi'an, China.
Zhengfa Xue *School of Computer Science and Technology, Xi'an Jiaotong University, Xi'an, China.
Jiayin Wang *School of Computer Science and Technology, Xi'an Jiaotong University, Xi'an, China.
Xinghao Ai *Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rongrong ChenGeneplus Beijing Institute, Beijing, China.
Xin YiGeneplus Beijing Institute, Beijing, China.
Shun LuShanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuqian LiuSchool of Computer Science and Technology, Xi'an Jiaotong University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with the target gene mutation frequently derive significant clinical benefits from target therapy. However, differences in the abundance level of mutations among patients resulted in varying survival benefits, even among patients with the same target gene mutations. Currently, there is a lack of rational and interpretable models to assess the risk of treatment failure

Indexed as

EGFRHosmer-Lemeshow testmulti-instance learningnon-small cell lung cancerrisk estimationtarget therapy

Identifiers

PMID39211737
PMCPMC11357964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.